Stock IRWD IRONWOOD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
6.54 USD +2.99% Intraday chart for Ironwood Pharmaceuticals, Inc. -3.96% -42.83%
Jun. 10 Ironwood Pharmaceuticals Insider Sold Shares Worth $517,694, According to a Recent SEC Filing MT
May. 22 Ironwood Pharmaceuticals Insider Sold Shares Worth $436,136, According to a Recent SEC Filing MT

Evolution of the average Target Price on Ironwood Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3fddfcf3649e2.LNk9k2J5ULMW2Pi2IPrhFcmzyzEs5hyRAYChHhItWHE.Sux2ogw1M8Z7j8uFU9eVI5jHiFtIkEjwdsPFSXBgMwNq4UT_KxUU2HShmw~be37049fa420637926cfa5f5b1f2ca19

Analyst Recommendations on Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals Insider Sold Shares Worth $517,694, According to a Recent SEC Filing MT
Ironwood Pharmaceuticals Insider Sold Shares Worth $436,136, According to a Recent SEC Filing MT
Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $21 From $20, Maintains Overweight Rating MT
Craig-Hallum Starts Coverage on Ironwood Pharmaceuticals with Buy Rating, $21 Price Target MT
JMP Securities Starts Ironwood Pharmaceuticals at Market Outperform, $22 Price Target MT
Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $19 From $16, Maintains Overweight Rating MT
Capital One Securities Initiates IRWD at Overweight with $15 Price Target MT
Wells Fargo Adjusts Ironwood Pharmaceuticals' Price Target to $13 from $12, Maintains Equalweight Rating MT
Piper Sandler Starts Ironwood Pharmaceuticals at Overweight With $16 Price Target MT
IRONWOOD PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Ironwood Pharmaceuticals to $14 From $13, Maintains Equal-Weight Rating MT
IRONWOOD PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Ironwood Pharmaceuticals to $12 From $11, Maintains Equal-Weight Rating MT
IRONWOOD PHARMACEUTICALS : Morgan Stanley Adjusts Ironwood Pharmaceuticals' Price Target to $12 from $11, Keeps Equalweight Rating MT
IRONWOOD PHARMACEUTICALS : Credit Suisse Adjusts Ironwood Pharmaceuticals' Price Target to $12 From $11, Maintains Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
6.54 USD
Average target price
15.83 USD
Spread / Average Target
+142.10%
High Price Target
23 USD
Spread / Highest target
+251.68%
Low Price Target
12 USD
Spread / Lowest Target
+83.49%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Ironwood Pharmaceuticals, Inc.

Piper Sandler
Craig-Hallum
JMP Securities
Capital One Securities
Wells Fargo Securities
Morgan Stanley

Ratings for Ironwood Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IRWD Stock
  4. Consensus Ironwood Pharmaceuticals, Inc.